Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions
- PMID: 16409998
- DOI: 10.1016/j.clinbiochem.2005.11.013
Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions
Abstract
Ocular angiogenesis may lead to visual impairment and even irreversible blindness in people of all ages worldwide. Choroidal neovascularization (CNV), a major clinical complication of ocular angiogenesis, is an important cause of vision loss that affects a large number of people. Physiological angiogenesis is tightly controlled by a balance in the expression of angiogenic and anti-angiogenic factors. While the underlying mechanism of CNV is complex, it is attributed to an upset in this balance. The vascular endothelial growth factor (VEGF) is essential in the development of CNV as one of the most potent angiogenic stimulators and vascular permeability factors. Pigment epithelium derived factor (PEDF) is a strong inhibitor of angiogenesis with high neuroprotective effects. VEGF and PEDF both possess multiple biological activities and functions that affect a large variety of tissue cells of the eye and other organs. Inappropriate expression levels are associated with many diseases involving neovascularization. This paper describes the unbalanced expressions of VEGF and PEDF as a cause of CNV. Based on the respective angiogenic and anti-angiogenic properties of VEGF and PEDF, experimental models have been devised to genetically reduce VEGF or enhance PEDF to achieve therapeutic effects. Gene therapy for CNV is promising and is under intensive research.
Similar articles
-
Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy.J Mol Endocrinol. 2006 Aug;37(1):1-12. doi: 10.1677/jme.1.02008. J Mol Endocrinol. 2006. PMID: 16901919
-
The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.Gynecol Endocrinol. 2009 Feb;25(2):104-9. doi: 10.1080/09513590802549841. Gynecol Endocrinol. 2009. PMID: 19253105
-
Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization.Invest Ophthalmol Vis Sci. 2002 Apr;43(4):1168-75. Invest Ophthalmol Vis Sci. 2002. PMID: 11923262
-
Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential.Prog Retin Eye Res. 2004 Sep;23(5):561-77. doi: 10.1016/j.preteyeres.2004.05.002. Prog Retin Eye Res. 2004. PMID: 15302351 Review.
-
[Mechanism of angiogenesis. Ocular involvement].Oftalmologia. 2003;59(4):3-8. Oftalmologia. 2003. PMID: 15083677 Review. Romanian.
Cited by
-
Characterization of the human aqueous humour proteome: A comparison of the genders.PLoS One. 2017 Mar 8;12(3):e0172481. doi: 10.1371/journal.pone.0172481. eCollection 2017. PLoS One. 2017. PMID: 28273097 Free PMC article.
-
Age-related macular degeneration: experimental and emerging treatments.Clin Ophthalmol. 2009;3:167-74. doi: 10.2147/opth.s5156. Epub 2009 Jun 2. Clin Ophthalmol. 2009. PMID: 19668561 Free PMC article.
-
Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration.J Control Release. 2023 Nov;363:464-483. doi: 10.1016/j.jconrel.2023.09.021. Epub 2023 Oct 4. J Control Release. 2023. PMID: 37774953 Free PMC article. Review.
-
gamma-Secretase: a multifaceted regulator of angiogenesis.J Cell Mol Med. 2008 Jun;12(3):781-95. doi: 10.1111/j.1582-4934.2008.00274.x. Epub 2008 Feb 8. J Cell Mol Med. 2008. PMID: 18266961 Free PMC article. Review.
-
Effect of zoledronate on the expression of vascular endothelial growth factor-a by articular chondrocytes and synovial cells: an in vitro study.J Bone Metab. 2014 Nov;21(4):249-55. doi: 10.11005/jbm.2014.21.4.249. Epub 2014 Nov 30. J Bone Metab. 2014. PMID: 25489573 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous